MétaCan
Menu
← Retour à la cohorte
Enregistrement W2993646328 · doi:10.1182/blood.v112.11.2681.2681

Implementation of Standardized International Karyotype Scoring Practices Is Needed to Provide Uniform and Systematic Evaluation for Patients with Myelodysplastic Syndrome Using IPSS Criteria: An International Working Group on MDS Cytogenetics Study

2008· article· en· W2993646328 sur OpenAlexaff
Kathy Chun, Anne Hagemeijer, M. Anwar Iqbal, Marilyn L. Slovak

Notice bibliographique

RevueBlood · 2008
Typearticle
Langueen
DomaineMedicine
ThématiqueAcute Myeloid Leukemia Research
Établissements canadiensNorth York General Hospital
Organismes subventionnairesnon disponible
Mots-clésInternational Prognostic Scoring SystemKaryotypeCytogeneticsMedicineMyelodysplastic syndromesOncologyInternal medicinePediatricsBiologyChromosomeBone marrowGenetics

Résumé

récupéré en direct d'OpenAlex

Abstract BACKGROUND: The International Prognosis Scoring System (IPSS) for evaluating the clinical outcome for patients with myelodysplastic syndromes is widely used to estimate overall survival and time of progression to acute myeloid leukemia. Karyotype status and complexity are key components of the IPSS; however, emerging data suggest the use of cytogenetics at disease presentation is not applied uniformly among MDS patients. AIM/METHODS: To investigate the degree of consistency of scoring karyotypes for IPSS among cytogeneticists and clinicians, the International Working Group on MDS Cytogenetics (IWGMC) conducted a survey of 32 karyotype challenges carried out in two phases: an initial survey without any specified karyotype counting guidelines and a second survey conducted after the development of IWGMC consensus guidelines for scoring karyotype complexity. The consensus guidelines for counting aberrations were: count 1 aberration for each numerical change (including –Y), balanced translocation and simple structural change; count 1 aberration for each complex structural change; count 0 for a constitutional aberration, but if in doubt, count 1 aberration; when multiple clones are present, add all independent aberrations, but count a single (specific) change only once; count 1 aberration for tetraploidy; and until it is revised, all chromosome 7 abnormalities are considered “poor”. The number of cytogenetic aberrations and the corresponding IPSS score (Good, Intermediate or Poor) were also to be given for each of the karyotypes. Twenty cytogeneticists and two clinicians participated in the initial survey. The second survey with attached IWGMC guidelines was completed by 23 cytogeneticists and 16 hematologists working at MDS Foundation Centers of Excellence worldwide. RESULTS: Despite the excellent concordance in the evaluation of simple karyotypic aberrations, major differences in scoring complex abnormalities were observed among the cytogeneticists who participated in the initial survey. After implementation of the IWGMC guidelines, scoring among the cytogeneticists in the second survey became homogeneous (<10% discrepant results). However, scoring among the hematologists remained much less consistent, with difficulties surrounding ploidy and complex rearrangements/karyotypes. These data and the results of a recent international physician’s practice survey conducted by the MDS Foundation, Inc., indicating 86% of 98 respondents state cytogenetic results had impact on their management of MDS patients and cytogenetic scoring is most often assigned by hematologists (67%), support the need for standardized karyotype scoring practices. These data also highlight that a number of unresolved issues with karyotype status and complexity scoring remain, including the status of –Y, classification of 7p abnormalities, and ploidy status and count. CONCLUSIONS: Our survey results indicate that cytogeneticists are capable of scoring karyotype complexity consistently with the consensus guidelines, whereas the hematologists remain slightly more puzzled by the nomenclature. Furthermore, despite these consensus guidelines, there remains a number of unresolved issues with karyotype status and complexity scoring. Therefore, our results argue for the immediate need of an international standardized complexity scoring system as well as a corresponding IPSS cytogenetic scoring system for clinical practice. We also argue that cytogeneticists must become more proactive in the management of MDS patients by implementing an immediate practice change that includes the IPSS karyotype score on the cytogenetics reports of all newly diagnosed MDS patients. Assisting the hematologists in this manner would ensure that cytogenetic data are applied in a uniform and systematic (comparable) manner, especially when new therapeutic approaches for MDS patients are being evaluated.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.

Comment cette classification a été obtenuedéplier

Prédiction machine sur la base complète

Imitation des enseignants

Ni prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.

score de la tête « metaresearch » (Codex)0,044
score de la tête « metaresearch » (Gemma)0,058
Version: metacan-v3-hybrid-931329e0061cStatut de validation: machine_predicted_unvalidated
Catégories candidatesMétarecherche
Catégories consensuellesaucune
DomaineSignal candidat: Méthodes · Signal consensuel: aucune
Devis d'étudeSignal candidat: Observationnel · Signal consensuel: Observationnel
GenreSignal candidat: Empirique · Signal consensuel: Empirique
Score de désaccord entre enseignants0,956
Score d'incertitude au seuil0,233

Scores du classifieur distillé par catégorie (deux têtes)

CatégorieCodexGemma
Métarecherche0,0440,058
Méta-épidémiologie (sens strict)0,0000,000
Méta-épidémiologie (sens large)0,0010,001
Bibliométrie0,0040,004
Études des sciences et des technologies0,0010,001
Communication savante0,0020,002
Science ouverte0,0010,003
Intégrité de la recherche0,0010,001
Charge utile insuffisante (le modèle a refusé de juger)0,0020,001

Scores machine (provisoires)

Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.

Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.

Tête enseignante Opus0,080
Tête enseignante GPT0,401
Écart entre enseignants0,321 · la distance entre les deux têtes enseignantes sur ce seul travail
Statut de validationscore_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle

Classification

machine, non validée

Prédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.

Devis d'étudeObservationnel
DomaineMéthodes
GenreEmpirique

Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».

En bref

Citations1
Publié2008
Routes d'admission1
Résumé présentoui

Explorer davantage

Même revueBlood→Même sujetAcute Myeloid Leukemia Research→Travaux en français237 207→